Novo Nordisk A/S (NYSE:NVO) Shares Sold by DE Burlo Group Inc.

DE Burlo Group Inc. lessened its holdings in shares of Novo Nordisk A/S (NYSE:NVO) by 13.8% in the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 148,730 shares of the company’s stock after selling 23,850 shares during the period. Novo Nordisk A/S accounts for approximately 2.2% of DE Burlo Group Inc.’s holdings, making the stock its 20th biggest position. DE Burlo Group Inc.’s holdings in Novo Nordisk A/S were worth $17,709,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently bought and sold shares of NVO. Massachusetts Financial Services Co. MA lifted its stake in Novo Nordisk A/S by 2.8% during the third quarter. Massachusetts Financial Services Co. MA now owns 79,660 shares of the company’s stock valued at $9,485,000 after purchasing an additional 2,166 shares during the last quarter. LPL Financial LLC increased its stake in Novo Nordisk A/S by 3.6% in the 3rd quarter. LPL Financial LLC now owns 1,362,782 shares of the company’s stock valued at $162,266,000 after buying an additional 47,496 shares during the period. Citizens Financial Group Inc. RI increased its stake in Novo Nordisk A/S by 1.9% in the 3rd quarter. Citizens Financial Group Inc. RI now owns 14,301 shares of the company’s stock valued at $1,703,000 after buying an additional 263 shares during the period. EagleClaw Capital Managment LLC increased its stake in shares of Novo Nordisk A/S by 4.1% during the 3rd quarter. EagleClaw Capital Managment LLC now owns 65,850 shares of the company’s stock worth $7,841,000 after purchasing an additional 2,575 shares during the last quarter. Finally, First Horizon Advisors Inc. increased its stake in shares of Novo Nordisk A/S by 55.5% during the 3rd quarter. First Horizon Advisors Inc. now owns 7,238 shares of the company’s stock worth $862,000 after purchasing an additional 2,582 shares during the last quarter. Institutional investors own 11.54% of the company’s stock.

Novo Nordisk A/S Trading Up 2.6 %

Shares of Novo Nordisk A/S stock opened at $105.30 on Thursday. The company has a market capitalization of $472.51 billion, a price-to-earnings ratio of 34.08, a PEG ratio of 1.32 and a beta of 0.42. The company has a quick ratio of 0.75, a current ratio of 0.94 and a debt-to-equity ratio of 0.43. Novo Nordisk A/S has a 12-month low of $94.73 and a 12-month high of $148.15. The firm’s 50-day moving average price is $116.80 and its two-hundred day moving average price is $129.11.

Analysts Set New Price Targets

NVO has been the subject of a number of research reports. Cantor Fitzgerald reissued an “overweight” rating and issued a $160.00 price target on shares of Novo Nordisk A/S in a report on Wednesday, November 6th. StockNews.com upgraded shares of Novo Nordisk A/S from a “buy” rating to a “strong-buy” rating in a report on Friday, November 1st. Finally, BMO Capital Markets reduced their target price on shares of Novo Nordisk A/S from $160.00 to $156.00 and set an “outperform” rating for the company in a report on Thursday, October 17th. One analyst has rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, Novo Nordisk A/S has a consensus rating of “Buy” and a consensus price target of $144.50.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.